Table 2.
Association of tumor-specific MHC-II/HLA-DR expression with outcome to pembrolizumab and NAC or chemotherapy alone.
pCR | RD | ||||||
---|---|---|---|---|---|---|---|
HLA-DR/DP/DQ/DX intensity units: | ≥17,000 (RPPA-high) n (%) | <17,000 (RPPA-low) n (%) | ≥17,000 (RPPA-high) n (%) | <17,000 (RPPA-low) n (%) | OR (95% CI)≥17,000 (RPPA-high) | χ2 P value (1-tailed) | |
All patients | Paclitaxel (n = 87) | 2 (2%) | 11 (13%) | 12 (14%) | 62 (71%) | 1.063 (0.23–5.3) | 0.47 |
Paclitaxel + pembrolizumab (n = 66) | 12 (18%) | 17 (26%) | 3 (2%) | 34 (55%) | 8 (1.938–28.42) | 0.0007 | |
HR+/HER2− | Paclitaxel (n = 49) | 2 (4%) | 5 (10%) | 7 (14%) | 35 (71%) | 2 (0.3381–10.37) | 0.22 |
Paclitaxel + pembrolizumab (n = 40) | 8 (20%) | 4 (10%) | 2 (5%) | 26 (65%) | 26 (4.253–136.3) | <0.0001 | |
TNBC | Paclitaxel (n = 38) | 0 (0%) | 6 (16%) | 5 (13%) | 27 (71%) | 0 (0.000–4.53) | 0.15 |
Paclitaxel + pembrolizumab (n = 26) | 4 (15%) | 13 (50%) | 1 (4%) | 8 (31%) | 2.46 (0.28–33.43) | 0.22 |
Note: Values in bold are statistically significant.